U.S. Banks Stock News

Beam Therapeutics has announced results from its ongoing Phase 1/2 trial of BEAM-302 for alpha-1 antitrypsin deficiency, reporting well-tolerated, dose-dependent mutation correction and durable restoration of functional alpha-1 antitrypsin protein in 17 treated patients as of August 1, 2025. Expansion into registrational development and the initiation of additional dose cohorts mark a potential shift for BEAM-302 as a possible single-course treatment for both liver and lung manifestations of...

Earlier in August 2025, Ball Corporation reported a strong second quarter with sales of US$3.34 billion and net income of US$212 million, and completed a significant share buyback, repurchasing nearly 13.9 million shares for US$731.35 million as part of its ongoing capital return program. The company raised its full-year 2025 guidance for comparable diluted earnings per share growth to 12%–15%, highlighting improved operational efficiency and confidence in sustained growth momentum. We'll...

UMH Properties, Inc. recently reported strong second quarter 2025 earnings, with revenue rising to US$66.64 million and net income reaching US$7.66 million, while management announced US$150 million in available capital for acquisitions and a proactive search for new opportunities. This combination of solid financial performance and readiness to pursue further growth opportunities highlights UMH's intent to expand its portfolio and strengthen its long-term earnings potential. We'll explore...

In August 2025, Zymeworks Inc. announced two new appointments to its Board of Directors, completed a private placement of 415,000 shares with board member Gregory A. Ciongoli, and reported a return to profitability in the second quarter with US$2.32 million in net income. This combination of leadership changes, direct board member investment, and a reversal from losses the prior year points to renewed confidence and a potentially stronger financial foundation for the company. Next, we'll...

Apellis Pharmaceuticals released its second quarter 2025 earnings results, reporting revenue of US$178.49 million and a net loss of US$42.15 million, both declining compared to the prior year period. This marks continued revenue and earnings pressure for the company, with basic loss per share from continuing operations widening year over year for both the quarter and first half. We will explore how these weaker quarterly results impact Apellis Pharmaceuticals' investment narrative,...

In the past week, Marathon Petroleum announced an expansion of its equity buyback authorization by US$1 billion to a total of US$51.1 billion and released second-quarter earnings reporting declines in sales, revenue, net income, and earnings per share year-over-year. The company also completed a share repurchase tranche worth US$692.09 million during the quarter, retiring over 4.76 million shares, highlighting its focus on shareholder returns despite softer financial results. Marathon's...

SBA Communications Corporation recently reported strong second quarter 2025 earnings, raising its full-year revenue and net income guidance and affirming its quarterly dividend, alongside completing a US$49.2 million share buyback tranche. These developments signal the company's financial confidence and capacity for shareholder returns while reinforcing its positive outlook amid ongoing wireless infrastructure demand. We'll explore how SBA Communications' upward revision of full-year...

Earlier this month, Dorman Products, Inc. announced its second quarter 2025 results, reporting US$540.96 million in sales and net income of US$58.71 million, both up from a year earlier, and raised its full-year earnings and sales growth guidance significantly. The upward revision in full-year guidance, particularly for diluted EPS and net sales growth, points to greater management confidence amid ongoing business momentum. Next, we'll examine how Dorman's increased full-year outlook...

Upstream Bio, Inc. recently announced its second quarter and first half 2025 results, reporting sales of US$937,000 for the quarter and a net loss of US$39.97 million, both higher than the previous year. While sales rose compared to the prior year, the company’s losses increased sharply, highlighting the ongoing balance between revenue growth and ongoing costs. We’ll explore how the increased losses despite sales growth could shape Upstream Bio’s investment narrative going forward. The end...

Innovex International reported second quarter 2025 results, with sales rising to US$224.23 million and net income reaching US$15.35 million, and issued third quarter revenue guidance between US$230 million and US$240 million. An important detail is that, while sales and net income improved, both basic and diluted earnings per share from continuing operations were lower than the prior year, pointing to shifts in profitability per share. We'll explore how the company's updated revenue guidance...

Planet Fitness, Inc. recently reported its second quarter 2025 results, with sales rising to US$138.99 million and net income increasing to US$58.02 million compared to the prior year, alongside announcing plans for 130 to 140 new equipment placements and 160 to 170 new franchisee-owned club openings. This combination of strong financial results and ambitious expansion plans points to confidence in business momentum and ongoing growth across the Planet Fitness system. We'll explore how...

Earlier this month, Maximus, Inc. reported third quarter 2025 earnings showing higher sales and net income, and also raised its full-year revenue guidance to between US$5.38 billion and US$5.48 billion. This combination of improved financial performance and upgraded outlook highlights management’s confidence in ongoing growth and the strength of demand for Maximus’ government-focused services. With full-year revenue guidance raised, we'll explore how Maximus' updated outlook impacts its...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

The board of Dominion Energy, Inc. ( NYSE:D ) has announced that it will pay a dividend of $0.6675 per share on the...

NasdaqCM:BTAI 1 Year Share Price vs Fair Value Explore BioXcel Therapeutics's Fair Values from the Community and select...

NasdaqCM:BWEN 1 Year Share Price vs Fair Value Explore Broadwind's Fair Values from the Community and select yours With...

NasdaqGS:NDLS 1 Year Share Price vs Fair Value Explore Noodles's Fair Values from the Community and select yours You...

As the U.S. stock market continues its rally, with major indices like the S&P 500 and Nasdaq reaching new all-time highs, investors are exploring diverse opportunities to capitalize on this momentum. Penny stocks, often perceived as relics of past trading days, still present intriguing prospects when backed by robust financials. In this article, we explore three penny stocks that stand out for their balance sheet strength and potential for significant returns, offering investors a chance to...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

NasdaqCM:SGML 1 Year Share Price vs Fair Value Explore Sigma Lithium's Fair Values from the Community and select yours...

NasdaqGS:CGEM 1 Year Share Price vs Fair Value Explore Cullinan Therapeutics's Fair Values from the Community and...

NasdaqCM:LIDR 1 Year Share Price vs Fair Value Explore AEye's Fair Values from the Community and select yours Legendary...

NasdaqGS:INGN 1 Year Share Price vs Fair Value Explore Inogen's Fair Values from the Community and select yours While...

NYSE:EVC 1 Year Share Price vs Fair Value Explore Entravision Communications's Fair Values from the Community and...